Longevity Industry in Switzerland: Landscape Overview 2019

Aging Analytics Agency's 475-page “Longevity Industry in Switzerland” report provides a comprehensive overview of the present state and near-future trajectory of the Longevity Industry in Switzerland in 2019, the country which is known for intensively developing its geroscience and FinTech to a state so advanced that it is now prepared for a central role in the internationally competitive Longevity business ecosystem, where it can rise to become a global leader in the specific field of Longevity finance.

The “Longevity Industry in Switzerland” report is structured so as to introduce readers to key developments in the Swiss Longevity sphere. This is accomplished by highlighting major Swiss players in the field of Longevity, covering pertinent scientific and technological advances, analyzing existing and projected governmental policies in Switzerland and by providing an overview of underlying demographic and economic data.

Why Switzerland?

Longevity-progressive countries normally have large aging populations. The Swiss population is one of the oldest on the planet. This is a consequence of low fertility, increased life expectancy (in 2018 Swiss life expectancy ranked 5th in the world, with an annual life expectancy of 83.489 years) and a societal appreciation for preventative health and healthy ageing. This induces Swiss organizations, companies, institutes, etc, to follow the global ageing trend and boosts Switzerland as a centre of biomedical research and technology in the Longevity sphere.

Switzerland is capable of retaining its position as one of the global leaders in the Longevity industry so long as it focuses on the optimal assembly of its existing resources, and further advances in technological spheres in order to face its economic and demographic challenges. Switzerland sits at a crossroads of European geroscience, and has a strong and productive geroscience community.

The top universities in Switzerland for clinical medicine, based on their reputation and research in the field are Zurich, Bern, Basel, Geneva, Lausanne, and the Swiss Federal Institute of Technology. Switzerland is also home to the prestigious Vontobel Prize for Aging Research.

Switzerland has gained prominence among investors as one of the two global hubs that have emerged as hotbeds of innovation for the resurgent biotech industry.

Switzerland sits at one end of the BioValley, one of the leading life science clusters in Europe. The cluster is unique in that it spans across three countries Switzerland, Germany and France. This includes the global life science hub of Basel. BioValley brings together important ingredients for a successful biotech cluster, a concentration of companies, rich availability of skills and experience within Life Sciences and a research base that is world-class.
Longevity Industry in Switzerland 2019

Companies - 100
Investors - 80
Research Labs - 80
Non-Profits - 15
Governmental - 10
Organizations

P3 Medicine

Governmental Organizations

Research Labs

Companies
Investors
Non-Profits
Regenerative Medicine

AgeTech

www.aginganalytics.com info@aginganalytics.com